Biotech Values

[pcrutch]

I imagine it will be between $30-60K based on a couple of sources that have listed some estimated pricings for Lemtrada based on projected revenues. How does Lemtrada's safety profile compare to Gilenya?

"Alemtuzumab, which is marketed under the name Campath, is currently available to patients with B-cell chronic lymphocytic leukemia (CLL) for $60,000 per year. However, MS patients require a fraction of the dosage for CLL, equating to $6,000 per year if priced relatively. The rebranding of alemtuzumab at lower doses will help Sanofi to justify a higher price point. The company's nearest competitor in the MS market, Novartis's Gilenya (fingolimod), costs upwards of $52,000 per year and Datamonitor believes that Sanofi will aim to price Lemtrada around this mark."

http://www.datamonitor.com/store/News/sanofi_lemtrada_will_emerge_as_a_key_ms_therapy_if_concerns_are_addressed?productid=EF2A1B41-2ADA-480D-85F2-11A92E3906B6

"The amount of Campath required to treat an M.S. patient at Campath’s prices is just $10,000."

http://www.bnet.com/blog/drug-business/sticker-shock-genzyme-may-want-60000-for-its-new-ms-drug/6867

"One possibility is that Genzyme will offer to supply the cancer patients with Campath free of charge. In return, the company would like the FDA’s permission to market alemtuzumab under a different name and charge the MS patients more than $30,000 a year."

http://www.bnet.com/blog/drug-business/can-genzyme-make-35b-a-year-giving-away-a-drug-for-free/6563?tag=content;drawer-container